NCT06711900View on ClinicalTrials.gov

A Study of SKB264 in Combination with Pembrolizumab Versus Chemotherapy in Combination with Pembrolizumab As First-Line Treatment for PD-L1 Negative Patients with Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

432

Participants

Timeline

Start Date

October 19, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

SKB264

IV Infusion

DRUG

Pembrolizumab

IV Infusion

DRUG

pemetrexed

IV Infusion

DRUG

carboplatin or cisplatin

IV Infusion

Trial Locations (1)

Unknown

RECRUITING

Shanghai Oriental Hospital, Shanghai

All Listed Sponsors
lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY